Bernstein analyst Eve Burstein lowered the firm’s price target on Avantor (AVTR) to $22 from $24.50 and keeps a Market Perform rating on the shares following quarterly results. The firm says the weakness in Avantor’s Laboratory Solutions business was the big concern this quarter: The segment missed expectations and quarterly guidance, and declined year-over-year.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Balanced Outlook on Avantor: Hold Rating Amidst Segment Underperformance and Strong Expense Management
- Favorable Risk-Reward Profile and Organic Growth Drive Buy Rating for Avantor
- Avantor price target lowered to $23 from $26 at Barclays
- Avantor Reports 2024 Financial Results, Shows Growth Potential
- Avantor Earnings Call: Balanced Outlook Amid Challenges